Characterisation of a P140K mutant O6- methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow

Journal of Gene Medicine

Volumn 8, Issue 9, 2006, Pages 1071-1085

  Kramer, Belinda A ^a,b   Lemckert, Frances A ^a   Alexander, Ian E ^a,b,c   Gunning, Peter W ^a,b   McCowage, Geoffrey B ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Allogeneic transplantation; DNA repair; Drug resistance; Mice; Stem cells; Transgenic

Indexed keywords

6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CD40 LIGAND MONOCLONAL ANTIBODY; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE P140K; OKT 8; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CHIMERA; CONTROLLED STUDY; DONOR; EMBRYO; EMBRYONIC STEM CELL; FEMALE; GENE EXPRESSION; GENE FUNCTION; HEMATOLOGIC MALIGNANCY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; MUTANT; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECIPIENT; STEM CELL GENE THERAPY; TRANSGENE; TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; CARMUSTINE; DNA; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POINT MUTATION; TRANSFECTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

MURINAE; MUS MUSCULUS;

EID: 33749256310     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.937     Document Type: Article

References (52)

1. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20: 2388-2399.
2. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res. 2000; 462: 83-100.
3. Hobin DA, Fairbairn LJ. Genetic chemoprotection with mutant O6-alkylguanine-DNA-alkyltransferases. Curr Gene Ther 2002; 2: 1-8.
4. Reese JS, Koc ON, Lee KM, et al. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc Natl Acad Sci U S A 1996; 93: 14088-14093.
5. Bobola MS, Berger MS, Ellenbogen RG, Roberts TS, Geyer JR, Silber JR. O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics. Clin Cancer Res 2001; 7: 613-619.
6. Hongeng S, Brent TP, Sanford RA, Li H, Kun LE, Heideman RL. O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clin Cancer Res 1997; 3: 2459-2463.
7. Brent TP, Houghton PJ, Houghton JA. O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc Natl Acad Sci U S A 1985; 82: 2985-2989.
8. Gerson SL, Berger NA, Arce C, Petzold SJ, Willson JK. Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine. Biochem Pharmacol 1992; 43: 1101-1107.
9. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990; 87: 5368-5372.
10. Gerson SL, Zborowska E, Norton K, Gordon NH, Willson JK. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharmacol 1993; 45: 483-4491.
11. Pegg AE, Swenn K, Chae MY, Dolan ME, Moschel RC. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N′-bis(2-chloroethyl)-N-nitrosourea. Biochem Pharmacol 1995; 50: 1141-1148.
12. Bibby MC, Thompson MJ, Rafferty JA, Margison GP, McElhinney RS. Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice. Br J Cancer 1999; 79: 1332-1339.
13. Gerson SL, Phillips W, Kastan M, Dumenco LL, Donovan C. Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Blood 1996; 88: 1649-1655.
14. Xu-Welliver M, Kanugula S, Pegg AE. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. Cancer Res 1998; 58: 1936-1945.
15. Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum Gene Ther 1999; 10: 2769-2778.
16. Ragg S, Xu-Welliver M, Bailey J, et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000; 60: 5187-5195.
17. Jansen M, Sorg UR, Ragg S, et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther 2002; 9: 737-746.
18. Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 2001; 3: 78-87.
19. Bowman JE, Reese JS, Lingas KT, Gerson SL. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Mol Ther 2003; 8: 42-50.
20. Neff T, Horn PA, Peterson LJ, et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 2003; 112: 1581-1588.
21. Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem HP. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005; 105: 997-1002.
22. Pollok KE, Hartwell JR, Braber A, et al. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther 2003; 14: 1703-1714.
23. Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 2003; 112: 1561-1570.
24. Davis BM, Humeau L, Dropulic B. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol Ther 2004; 9: 160-172.
25. Richard E, Robert E, Cario-Andre M, et al. Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection. Gene Ther 2004; 11: 1638-1647.
26. Persons DA, Allay ER, Sawai N, et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003; 102: 506-513.
27. Salmon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, Trono D. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 2000; 96: 3392-3398.
28. Mikkola H, Woods NB, Sjogren M, et al. Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells. J Virol 2000; 74: 11911-11918.
29. Chung S, Andersson T, Sonntag KC, Bjorklund L, Isacson O, Kim KS. Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines. Stem Cells 2002; 20: 139-145.
30. Lemckert FA, Sedgwick JD, Korner H. Gene targeting in C57BL/6 ES cells. Successful germ line transmission using recipient BALB/c blastocysts developmentally matured in vitro. Nucleic Acids Res 1997; 25: 917-928.
31. Robertson G, Garrick D, Wilson M, Martin DI, Whitelaw E. Age-dependent silencing of globin transgenes in the mouse. Nucleic Acids Res 1996; 24: 1465-1471.
32. Martin DI, Whitelaw E. The vagaries of variegating transgenes. Bioessays 1996; 18: 919-923.
33. Mitruka BJ, Rawnsley HM. Clinical Biochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans, Masson Publishing USA Inc.: New York, 1977.
34. Ruffner KL, Martin PJ, Hussell S, et al. Immunosuppressive effects of 1311-anti-CD45 antibody in unsensitised and donor antigen-presensitized H2-matched, minor-antigen-mismatched murine transplant models. Cancer Res 2001; 61: 5126-5131.
35. Adams AB, Durham MM, Kean L, et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001; 167: 1103-1111.
36. Andersson G, Illigens BM, Johnson KW, et al. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood 2003; 101: 4305-4312.
37. Lieu FH, Hawley TS, Fong AZ, Hawley RG. Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy. Cancer Gene Ther 1997; 4: 167-175.
38. Chen BF, Hwang LH, Chen DS. Characterization of a bicistronic retroviral vector composed of the swine vesicular disease virus internal ribosome entry site. J Virol 1993; 76: 2142-2148.
39. Lemischka IR. Clonal, in vivo behavior of the totipotent hematopoietic stem cell. Semin Immunol 1991; 3: 349-355.
40. Drize NJ, Olshanskaya YV, Gerasimova LP, et al. Lifelong hematopoiesis in both reconstituted and sublethally irradiated mice is provided by multiple sequentially recruited stem cells. Exp Hematol 2001; 29: 786-794.
41. Opsahl ML, McClenaghan M, Springbett A, et al. Multiple effects of genetic background on variegated transgene expression in mice. Genetics 2002; 160: 1107-1112.
42. Dobie KW, Lee M, Fantes JA, et al. Variegated transgene expression in mouse mammary gland is determined by the transgene integration locus. Proc Natl Acad Sci U S A 1996; 93: 6659-6664.
43. Robertson G, Garrick D, Wu W, Kearns M, Martin D, Whitelaw E. Position-dependent variegation of globin transgene expression in mice. Proc Natl Acad Sci U S A 1995; 92: 5371-5375.
44. Ramirez A, Milot E, Ponsa I, et al. Sequence and chromosomal context effects on variegated expression of keratin 5/lacZ constructs in stratified epithelia of transgenic mice. Genetics 2110; 158: 341-350.
45. Reese JS, Qin X, Ballas CB, Sekiguchi M, Gerson SL. MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure. J Hematother Stem Cell Res 2001; 10: 115-123.
46. Dumenco LL, Allay E, Norton K, Gerson SL. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science 1993; 259: 219-222.
47. Nakatsuru Y, Matsukuma S, Nemoto N, Sugano H, Sekiguchi M, Ishikawa T. O6-Methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc Natl Acad Sci U S A 1993; 90: 6468-6472.
48. Becker K, Dosch J, Gregel CM, Martin BA, Kaina B. Targeted expression of human O(6)-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. Cancer Res 1996; 56: 3244-3249.
49. Zhou ZQ, Manguino D, Kewitt K, et al. Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6-methylguanine-DNA methyltransferase. Proc Natl Acad Sci USA 2001; 98: 12566-12571.
50. Liu L, Qin X, Gerson SL. Reduced lung tumorigenesis in human methylguanine DNA-methyltransferase transgenic mice achieved by expression of transgene within the target cell. Carcinogenesis 1999; 20: 279-284.
51. Ito H, Kurtz J, Shaffer J, Sykes M. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001; 166: 2970-2981.
52. Kean LS, Durham MM, Adams AB, et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 2002; 99: 1840-1849.